Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 227,692,647 papers from all fields of science
Search
Sign In
Create Free Account
AC 7700
Known as:
AVE8062
, Combretastatin A4 Analogue AVE8062
, AC7700
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
3 relations
Broader (1)
Serine
analogs & derivatives
Narrower (1)
ombrabulin
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2014
Review
2014
New vascular disrupting agents in upper gastrointestinal malignancies.
A. E. Quatrale
,
L. Porcelli
,
A. Gnoni
,
G. Numico
,
Angelo Paradiso
,
A. Azzariti
Current Medicinal Chemistry
2014
Corpus ID: 33181541
Antivascular approaches aim to cause rapid and catastrophic shutdown in the vascular function of the tumour, leading to extensive…
Expand
Review
2013
Review
2013
Combretastatin A-4 and its Analogs in Cancer Therapy
S. Arora
,
Andrés González
2013
Corpus ID: 36284638
Combretastatin A-4 (CA-4) is an anti-mitotic agent that is gaining rapid recognition among cancer biologists and clinicians as…
Expand
2008
2008
A comprehensive study of translational research and safety exploration of the vascular disrupting agent (VDA) AVE8062 in combination with cisplatin administered every 3 weeks to patients with…
J. Soria
,
C. Sessa
,
+6 authors
L. Gianni
2008
Corpus ID: 58784378
AACR Annual Meeting-- Apr 12-16, 2008; San Diego, CA LB-302 Abstract LB-302 is scheduld in a Late-Breaking Abstract session…
Expand
Review
2007
Review
2007
Small molecule vascular disrupting agents: potential new drugs for cancer treatment.
S. Cai
Recent Patents on Anti-Cancer Drug Discovery
2007
Corpus ID: 25873315
Vascular disrupting agents (VDAs) are a new class of potential anticancer drugs that selectively destroy tumor vasculature and…
Expand
2006
2006
In vivo synergy combining oxaliplatin with AVE8062, a vascular-disrupting agent.
B. Demers
,
P. Vrignaud
,
M. Bissery
Journal of Clinical Oncology
2006
Corpus ID: 27245310
13074 Background: AVE8062 is a synthetic, water-soluble compound, analog of Combretastatin A4, currently in Phase I clinical…
Expand
Review
2005
Review
2005
Antineoplastic Strategy: Irreversible Tumor Blood Flow Stasis Induced by the Combretastatin A-4 Derivative AVE8062 (AC7700)
K. Hori
Chemotherapy
2005
Corpus ID: 24627861
Despite extensive research efforts, effective therapies for refractive cancers have not yet been established, and development of…
Expand
2002
2002
Antitumor and antivascular effects of AC-7700, a combretastatin A-4 derivative, against rat liver cancer
T. Ohno
,
K. Kawano
,
+4 authors
S. Kitano
International Journal of Clinical Oncology
2002
Corpus ID: 2267436
AbstractBackground. Unlike the many chemotherapeutic agents that do not effectively stop blood flow or induce necrosis in…
Expand
2001
2001
Stoppage of blood flow in 3-methylcholanthrene-induced autochthonous primary tumor due to a novel combretastatin A-4 derivative, AC7700, and its antitumor effect.
K. Hori
,
S. Saito
,
Y. Sato
,
K. Kubota
Medical Science Monitor
2001
Corpus ID: 40658867
BACKGROUND Using several transplanted tumors in rats and mice, we have recently shown that the acute extensive necrosis of tumor…
Expand
Highly Cited
1999
Highly Cited
1999
Evaluation of Antivascular and Antimitotic Effects of Tubulin Binding Agents in Solid Tumor Therapy
Y. Nihei
,
Manabu Suzuki
,
+6 authors
Yasufumi Sato
Japanese journal of cancer research : Gann
1999
Corpus ID: 13724831
Tubulin binding agents (TBAs) reduce tumor perfusion and inhibit mitosis of tumor cells in solid tumors, but it is not clear…
Expand
1999
1999
Synthesis and antitumor activities of amino acid prodrugs of amino-combretastatins.
K. Ohsumi
,
T. Hatanaka
,
+7 authors
T. Tsuji
Anti-Cancer Drug Design
1999
Corpus ID: 44929034
The synthesis and antitumor activity of water-soluble amino acid prodrugs of amino-combretastatins were reported. Among the…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE